Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Multiple Ascending-Dose Study of ARCT-032 in Cystic Fibrosis
2024-517663-23-01Phase 2Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Jul 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ARCT-032 in cystic fibrosis (CF), sponsored by Arcturus Therapeutics. Primary endpoints: Safety and tolerability of ARCT-032 via adverse events, Changes from baseline in vital signs and 3 more. Started Jul 2025; status: completed.
02
Drugs
ARCT-032
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-517663-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517663-23-01.